Abbott Laboratories(ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Latest News & Analysis
Abbott Laboratories Q2 2025 Analysis: Medical Device Growth Amid Diagnostics Challenges
Explore Abbott Laboratories' Q2 2025 performance, focusing on medical device innovation, diagnostics segment headwinds, dividend sustainability, and strategic growth drivers.
Abbott Laboratories Q2 2025 Earnings: Medical Devices Drive Growth Amid Diagnostics Challenges
Abbott Laboratories reports strong Q2 2025 sales growth led by Medical Devices, while Diagnostics face headwinds prompting a cautious full-year guidance revision.
Abbott Laboratories (ABT) Surges on Robust Earnings and Strategic Financial Strength
Abbott Laboratories stock rises +3.53% post strong earnings beat; deep dive into financials, cash flow, and strategic positioning for investors.
Abbott Laboratories Q2 Analysis: Medical Device Growth Drives Strong Financials | Monexa AI
Abbott Laboratories' Q2 growth is fueled by its Medical Devices segment, with strong CGM and cardiac device sales underpinning robust financial performance.
Abbott Laboratories (ABT) Latest Corporate Update and Financial Analysis
Explore Abbott Laboratories' recent developments, financial performance, and strategic positioning amid evolving healthcare market dynamics.
Abbott Laboratories (ABT) Growth Drivers and Financial Strength Fuel Investor Confidence
Abbott Laboratories' innovation in medical devices and FreeStyle Libre platform, combined with strong financials, drive sustainable growth and shareholder value.
Abbott Laboratories (ABT) Latest Developments: FreeStyle Libre Growth, Innovation, and Financial Strength
Explore Abbott Laboratories' recent growth driven by FreeStyle Libre, medical device innovation, and robust financial performance, shaping its market leadership.
Abbott Laboratories (ABT) Latest Innovations and Financial Performance Analysis
Abbott Laboratories advances with FDA-approved Tendyne valve and FreeStyle Libre growth, supported by strong financials and strategic R&D investment.
Abbott Laboratories (ABT): Innovation Fuels Q1 2025 Success and Outlook
Abbott Laboratories' Q1 2025 results reveal robust growth, driven by groundbreaking innovations in cardiac care, diabetes management, and diagnostics.
Abbott Laboratories (ABT): Profitability Surge & Strategic Innovation in 2025
Abbott Laboratories' 2024 financial results reveal a strategic pivot towards enhanced profitability, marked by a significant net income surge.
Abbott Laboratories (ABT): Financial Surge, Strategic Innovation & Dividends
Abbott Laboratories showcases robust financial health and strategic innovation, with a 134.27% surge in net income and continued dividend leadership.
Abbott Laboratories' Strategic Advances: FDA Approvals & Dividend Strength
Abbott Laboratories' recent FDA approval of the Tendyne TMVR system and advancements in Libre CGM technology are reshaping its market position and financial trajectory.
Abbott Laboratories (ABT): Net Income Surge and Strategic Wins
Abbott Laboratories sees a surge in net income, driven by strategic wins in cardiac devices and diabetes care, signaling robust operational performance.
Abbott (ABT): Volt PFA Approval, TriClip Success, and Market Outlook
Abbott Laboratories (ABT) navigates market volatility with Volt PFA approval, TriClip success, and a consistent dividend history, making it a stable investment.
Abbott (ABT): PFA Approval, Coronary IVL System, and Market Outlook
Abbott Laboratories (ABT) gains momentum with CE Mark approval for Volt™ PFA and FDA IDE nod for Coronary IVL, bolstering its cardiovascular portfolio.
Abbott (ABT): FDA Approval, Market Impact, and Future Growth
Analysis of Abbott Laboratories (ABT): FDA approval for Coronary IVL System, AI initiatives, dividend growth, and strategic focus on diabetes care and weight-loss.
Abbott Laboratories: Coronary IVL, Weight Loss, and AI Driving Growth
Abbott Laboratories is strategically positioned for growth through medical devices, expansion into weight-loss, and AI integration. Dividend payouts and financial stability enhance its appeal.
Abbott (ABT): Growth, Dividends, and Market Outlook 2025
Abbott Laboratories (ABT) navigates market dynamics with strategic expansions, FreeStyle Libre advancements, and dividend reliability. A detailed analysis for investors.
Abbott Laboratories (ABT): Earnings, Dividends, and Growth Analysis
A deep dive into Abbott Laboratories' recent performance, dividend aristocrat status, and growth prospects. Discover how strategic initiatives and market dynamics shape ABT's future.
Abbott Laboratories: Intraday Market Update - March 5, 2025
Intraday update on Abbott Laboratories (ABT) with key financial metrics, dividend news, strategic moves, and market trends from credible sources.
Abbott Laboratories: Analyzing Growth Drivers and Future Outlook
Abbott Laboratories (ABT) navigates 2025 with strong performance, driven by FreeStyle Libre and molecular diagnostics, despite FX headwinds. Dividend Aristocrat status enhances investor appeal.
Abbott (ABT) in 2025: Dividend King, Diabetes Care Leader
Abbott Laboratories (ABT) shows strong 2025 performance driven by dividends, diabetes care, and diagnostics growth, despite FX risks. A detailed analysis follows.
Abbott Laboratories (ABT): Growth, Dividends, and Market Leadership
Comprehensive analysis of Abbott Laboratories (ABT): exploring diabetes care innovations, molecular diagnostics growth, dividend consistency, and future outlook.
Abbott Laboratories (ABT): Navigating Growth in Diabetes Care & Diagnostics
**Abbott Laboratories (ABT) demonstrates resilience and growth potential.** Driven by FreeStyle Libre and expansion in molecular diagnostics, the company maintains a steady climb.
Abbott Laboratories: Growth Drivers, Market Trends, and Future Outlook
Abbott Laboratories navigates a dynamic healthcare landscape with consistent dividends, FreeStyle Libre growth, and molecular diagnostics opportunities. A comprehensive analysis of ABT's market position.
Abbott Laboratories: Dividends, Diabetes Care & Market Trends
Abbott continues to deliver consistent dividends, robust diabetes care growth, and expanding diagnostics in a competitive healthcare landscape.
Abbott Laboratories: Navigating Growth in Diabetes Care
Abbott Laboratories demonstrates resilience amid market volatility, driven by growth in diabetes care and strategic market expansion. ABT stock increases +0.79%.
Abbott Laboratories: Navigating Growth in Diagnostics, Diabetes Care, and Dividends
A comprehensive data-driven analysis of Abbott’s Q4 performance, R&D investments, and market trends shaping its future.